EUVIMEDEUVIMED entdecken
Open Access

MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRAS Q61R Human Endothelial Cells

Sara Alharbi iD, Andrew Wagner iD, Svatava Merkle iD, Patricia Pastura, C Griffin McDaniel iD, Dermot Fox, Yan Xu, Timothy D Le Cras iD

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Sara Alharbi und 7 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Endothelial Cells, Membrane Proteins, GTP Phosphohydrolases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Lymphatic Malformation Institute, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An activating NRAS p .Q61R ( NRAS Q61R ) somatic mutation occurs in the lesions of patients with kaposiform lymphangiomatosis (KLA). Therapies for KLA patients are limited and since the mitogen‐activated protein kinase pathway is hyperactivated by NRAS Q61R , we evaluated the potency of Mitogen‐activated protein kinase kinase (MEK) inhibitors (trametinib, selumetinib, and cobimetinib) on human NRAS Q61R endothelial cells (ECs). RNA sequencing analysis was performed to identify dysregulated genes and those restored by trametinib. Trametinib was tested in a mouse xenograft model of NRAS Q61R ECs. Procedure Doxycycline (Dox)‐inducible NRAS Q61R ECs were treated with trametinib, selumetinib, cobimetinib, or vehicle (control). Cell signaling pathways, proliferation, migration, morphology, and angiopoietin‐2 (ANG‐2) levels were assessed. RNA‐sequencing analysis was performed on Dox‐induced NRAS wild‐type ( NRAS WT ), NRAS Q61R , and trametinib‐treated NRAS Q61R ECs. Selected proteins were verified by immunoblotting. NRAS Q61R ECs were injected into nude mice on Dox‐containing diet to generate xenografts and treated with trametinib or vehicle.

Results

Trametinib reduced NRAS Q61R ‐activated ERK phosphorylation, cell proliferation, migration, spindling, and ANG‐2 at lower doses than selumetinib or cobimetinib. RNA‐sequencing detected 1315 upregulated and 1773 downregulated genes in NRAS Q61R ECs compared with NRAS WT . Trametinib corrected 19% upregulated and 8% downregulated genes, including elevated Notch ligands (DLL4, JAG1), activated Notch 1, and HES1. Trametinib reduced NRAS Q61R ECs xenograft weights by 46%, vascular area by 63%, and phosphorylated ERK staining.

Conclusion

Trametinib was the most effective MEK inhibitor, correcting some dysregulated genes in NRAS Q61R ECs, including some in the Notch pathway. Trametinib reduced vessel overgrowth in xenografts of NRAS Q61R ECs. These studies support using trametinib treatment for KLA patients with an NRAS Q61R mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelial CellsMembrane ProteinsGTP PhosphohydrolasesProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesHumansAnimalsMicePyridonesPyrimidinonesBenzimidazolesXenograft Model Antitumor AssaysHemangioendotheliomaMice, NudeCell ProliferationMutationAzetidinesPiperidines

Stichwörter der Autor:innen

cobimetinibkaposiform lymphangiomatosisselumetinibtrametinibvascular anomalies

Substanzen

NRAS protein, humantrametinibMembrane ProteinsGTP PhosphohydrolasesPyridonesProtein Kinase InhibitorsPyrimidinonescobimetinibBenzimidazolesMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • 1Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

ORCID-Profile: Sara Alharbi, Andrew Wagner, Svatava Merkle, C Griffin McDaniel, Timothy D Le Cras

Förderung

  • Lymphatic Malformation Institute
  • NHLBI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Alharbi, S., Wagner, A., Merkle, S., Pastura, P., McDaniel, C. G., Fox, D., Xu, Y., & Le Cras, T. D. (2026). MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRAS Q61R Human Endothelial Cells. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70002

Vancouver

Alharbi S, Wagner A, Merkle S, Pastura P, McDaniel CG, Fox D, et al. MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRAS Q61R Human Endothelial Cells. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70002

BibTeX
@article{Alharbi2026,
  author = {Alharbi, Sara and Wagner, Andrew and Merkle, Svatava and Pastura, Patricia and McDaniel, C Griffin and Fox, Dermot and Xu, Yan and Le Cras, Timothy D},
  title = {MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRAS Q61R Human Endothelial Cells},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70002}
}
Kostenlos starten →